[Association between lithium sensitivity and GSK3beta gene polymorphisms in bipolar disorder]

Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Jun;32(3):161-3.
[Article in Japanese]

Abstract

GSK-3beta codes for an enzyme which is a target for the action of mood stabilizers, lithium and possibly of valproic acid. The relationship between the polymorphisms (SNPs) of GSK-3beta-50T/C and -1727A/T and the effect of lithium was studied among 29 Japanese bipolar patients. It was shown that GSK-3beta-50T/C may be linked with the effect of lithium treatment. There is a significantly higher T-allele frequency in the lithium responders than non-responders (df = 1, chi2 = 6.971, 0.01 > P > 0.001; Yates' continuity correction). However, there is not a significant relationship between the polymorphisms of GSK-3beta-1727A/T and the effect of lithium treatment.

MeSH terms

  • Adult
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / genetics*
  • Gene Frequency / genetics
  • Glycogen Synthase Kinase 3 / genetics*
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Lithium / therapeutic use*
  • Middle Aged
  • Polymorphism, Single Nucleotide*

Substances

  • Lithium
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Glycogen Synthase Kinase 3